KalVista Pharmaceuticals’ (KALV) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a research report report published on Friday,Benzinga reports. The brokerage currently has a $20.00 price objective on the specialty pharmaceutical company’s stock.

Several other research analysts also recently weighed in on the stock. TD Cowen initiated coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective on the stock. Finally, Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $23.80.

KalVista Pharmaceuticals Trading Up 2.9 %

KALV opened at $12.60 on Friday. The company’s fifty day moving average price is $9.67 and its two-hundred day moving average price is $10.30. KalVista Pharmaceuticals has a 1-year low of $7.30 and a 1-year high of $15.50. The company has a market cap of $622.67 million, a price-to-earnings ratio of -3.46 and a beta of 0.76.

Insider Activity

In related news, major shareholder Venrock Healthcare Capital Par purchased 43,707 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Thursday, January 30th. The stock was bought at an average price of $8.76 per share, for a total transaction of $382,873.32. Following the completion of the transaction, the insider now owns 4,986,480 shares in the company, valued at $43,681,564.80. This represents a 0.88 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Paul K. Audhya sold 3,125 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $30,687.50. Following the transaction, the insider now owns 100,334 shares of the company’s stock, valued at approximately $985,279.88. The trade was a 3.02 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders bought 236,055 shares of company stock worth $2,162,146 and sold 17,292 shares worth $184,625. 10.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Aquatic Capital Management LLC bought a new position in KalVista Pharmaceuticals during the fourth quarter valued at about $44,000. Tower Research Capital LLC TRC grew its position in KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 5,502 shares during the period. Legal & General Group Plc boosted its position in KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 1,494 shares during the period. Martin Worley Group bought a new position in KalVista Pharmaceuticals during the fourth quarter worth about $86,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after purchasing an additional 2,043 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).